Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Streck and Orgentec Sasu, a distributor in France that specializes in the in vitro diagnosis of autoimmunity, infectious diseases, molecular biology, internal/external quality control, biochemistry, and sedimentation rate, have signed an exclusive distribution agreement for Streck’s cell stabilization and molecular products.
December 2017—Binding Site’s Immunologicals Group has added eight recombinant antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The recombinant Parvovirus NS1, Parvovirus VP1, Parvovirus VP2, Parvovirus VP2-VLP, Parvovirus PepA (VP1 unique), Parvovirus PepB (VP2 C-term), Parvovirus PepC (VP1 N-term), and Parvovirus PepD (VP1 C-term) have been designed for use as an integral component within solid phase enzyme immunoassay test procedures, including ELISA.
December 2017—Horizon Discovery’s Dharmacon announced the launch of its CRISPR activation reagent platform, the latest addition to the company’s Edit-R portfolio for CRISPR-Cas9 genome engineering.
December 2017—Chembio Diagnostics received FDA emergency use authorization for its DPP Zika System. The system, for use in high- and moderate-complexity CLIA-certified laboratories, provides results in 15–20 minutes from 10 µL of blood and includes the DPP Zika IgM Assay and DPP Micro Reader.
December 2017—Beckman Coulter Diagnostics announced its Access 2 immunoassay system is available with enhanced features that aim to improve ease of use, workflow efficiencies, system reliability, and customer satisfaction.
December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.
December 2017—Aushon BioSystems and ABL announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. ABL will offer this proprietary technology as a new addition to its service offerings in support of pharmaceutical and clinical research clients.
December 2017—Binding Site’s Immunologicals Group offers a comprehensive line of disease state sera in its portfolio of products available to in vitro diagnostic manufacturers and clinical research facilities. The line of products follows all current regulatory and quality standards guidelines and provides materials from a variety of disease state conditions, including ANAs, ANCAs, aPLs, ENAs, infectious and contagious diseases, inflammation markers, and autoantibodies focused on a variety of human organs and tissues.
December 2017—DiaSorin Molecular introduced group C and group G Streptococcus primer pairs and a Pneumocystis jirovecii primer pair for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers.
December 2017—Promega Corp.’s bioluminescent HiBiT Protein Tagging System can be combined with CRISPR/Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions, as demonstrated in a study published in ACS Chemical Biology (Schwinn MK, et al. Epub ahead of print Sept. 21, 2017. doi:10.1021/acschembio.7b00549).
